Ontology highlight
ABSTRACT:
SUBMITTER: Balachandran VP
PROVIDER: S-EPMC3278279 | biostudies-literature | 2011 Aug
REPOSITORIES: biostudies-literature
Nature medicine 20110828 9
Imatinib mesylate targets mutated KIT oncoproteins in gastrointestinal stromal tumor (GIST) and produces a clinical response in 80% of patients. The mechanism is believed to depend predominantly on the inhibition of KIT-driven signals for tumor-cell survival and proliferation. Using a mouse model of spontaneous GIST, we found that the immune system contributes substantially to the antitumor effects of imatinib. Imatinib therapy activated CD8(+) T cells and induced regulatory T cell (T(reg) cell) ...[more]